Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir in Recurrent Positive COVID-19 Patients
NCT04333589Unknown
- Sponsor
- Peking University First Hospital
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of favipiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Viral nucleic acid test negative conversion rate at 5 months. Status: unknown.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04333589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333589.